Ainos Reports Full Year 2023 Financial Results
- Ainos, Inc. successfully navigated a year of transition in 2023, focusing on diversifying its business model post-COVID era.
- The company made significant progress in expanding the addressable market for its AI Nose technology with strategic partners NISD and Inabata.
- Ainos advanced the manufacturing of VELDONA investigational new drugs and commenced shipping VELDONA Pet cytoprotein supplements in Taiwan.
- Despite reduced demand for COVID-19 test kits impacting revenues, Ainos maintained a stable headcount, showcasing resilience and cost-effective operations.
- The company aims to pivot away from COVID-19 test kits sales, focusing on VELDONA Pet, Ainos Flora, and VOC sensing platform development in 2024.
- Ainos strengthened its financial position in 2023 through private placements and convertible promissory notes, supporting its growth strategy.
- The company reported a decrease in revenues, gross profit, and net loss in 2023 compared to 2022, primarily due to reduced demand for COVID-19 test kits.
- Operating expenses decreased in 2023, with R&D expenses increasing while SG&A expenses decreased.
- Ainos had a net loss of US$13,770,549 in 2023, with cash and cash equivalents of US$1,885,628 as of December 31, 2023.
- Recent business developments include partnerships with SIDSCO Biomedical Co., Ltd., positive clinical data for VELDONA low-dose oral interferon formulation, and progress in VOC sensing platform development.
- Significant decrease in revenues from US$3,519,627 in 2022 to US$122,112 in 2023 due to reduced demand for COVID-19 test kits.
- Negative gross profit of US$253,733 in 2023 compared to positive gross profit of US$1,405,343 in 2022.
- Net loss attributable to common stock shareholders was US$13,770,549 in 2023, indicating a financial loss for the company.
- While operating expenses decreased in 2023, R&D expenses increased, impacting the overall financial performance of the company.
- Ainos' financial position was weakened in 2023, with a decrease in cash and cash equivalents compared to the previous year.
Insights
The financial results of Ainos, Inc. for the year ended December 31, 2023, highlight a significant decrease in revenue, primarily due to a reduced demand for COVID-19 test kits. This decline is reflected in the year-over-year revenue drop from US$3,519,627 in 2022 to US$122,112 in 2023. The company's shift towards diversification, including the advancement of VELDONA drug candidates and the expansion of AI Nose-powered VOC-sensing technology, is a strategic move to mitigate the impact of this reduced demand. However, the net loss of US$13,770,549, although slightly improved from the previous year's US$14,006,690, indicates that the company is still facing financial challenges.
From an investment perspective, the increase in R&D expenses to US$7,317,388, despite the decrease in share-based compensation, suggests that Ainos is investing heavily in its future product pipeline. The collaboration with strategic partners, such as NISD and Inabata and the successful manufacturing of a GMP clinical batch of VELDONA investigational new drugs, are positive indicators of progress in product development. However, the negative gross profit and the need for additional capital, as evidenced by the private placement and convertible promissory notes, raise concerns about the company's current financial stability and the time frame required to achieve profitability.
The progression of Ainos' VELDONA drug candidates into Phase III clinical studies is a critical milestone in the pharmaceutical development process. Phase III trials are pivotal in determining the efficacy and safety of a drug and are often the last step before seeking regulatory approval. The positive top-line data from clinical studies for the VELDONA low-dose oral interferon formulation, particularly its efficacy in treating oral warts in HIV-seropositive patients, which has received Orphan Drug Designation from the FDA, is a strong indicator of the drug's potential. This designation provides certain benefits, including market exclusivity upon approval, which could significantly impact the company's future revenue streams if the drug is successful.
Furthermore, the expansion into the pet care market with the VELDONA Pet cytoprotein supplements and the exploration of contract clinical trials with SIDSCO for veterinary investigational medicines could open new revenue channels. The diversification into pet care, a robust and growing market, aligns with broader industry trends where companies expand beyond human health into animal health to leverage existing expertise and create additional income sources.
The strategic pivot towards AI-powered point-of-care testing and VOC-sensing technology represents Ainos' response to the evolving healthcare landscape. The initiation of the second phase of collaboration with NISD and Inabata to co-develop an AI Nose-powered VOC sensing platform is particularly noteworthy. The potential applications of this technology across industries such as telehealth, automotive, industrial and environmental safety suggest that Ainos is targeting a multi-sector approach, which could lead to a diversified and resilient business model.
The VOC-sensing technology market is growing, driven by the need for improved diagnostic tools and environmental monitoring solutions. Ainos' entry into this market, especially if they can achieve mass production following the successful finalization of the prototype, could position the company at the forefront of a niche yet expanding segment. The company's ability to maintain a stable headcount amidst widespread downsizing in the healthcare industry further indicates operational efficiency, which is a positive sign for potential investors and partners.
Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024
Advancing VELDONA drug candidates to Phase III clinical studies
Expanding market of AI Nose-powered VOC-sensing technology with strategic partners NISD and Inabata
SAN DIEGO, CA / ACCESSWIRE / March 8, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the year ended December 31, 2023.
Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "In 2023, we navigated a year of transition and successfully advanced the shift of our business model to align with the post-COVID era. Although we faced reduced demand for COVID-19 test kits, impacting our revenues during 2023, we have made noteworthy strides in diversifying our business for sustained growth, reaching key milestones that we anticipate will catalyze the development and commercialization of our product pipeline in the coming years."
"First, we moved closer to expanding the potential addressable market for our AI Nose with initiation of the second phase of our collaboration with Nisshinbo Micro Devices Inc. ("NISD") and Taiwan Inabata Sangyo Co ("Inabata"). Together, we are co-developing an AI Nose-powered VOC sensing platform with potential applications spanning a wide variety of industries, including telehealth, automotive, industrial, and environmental safety. Second, in November, our contract manufacturer Swiss Pharma completed manufacturing of a Good Manufacturing Practice clinical batch of VELDONA® investigational new drugs. This advances one of our key programs and has the potential to ultimately facilitate delivery of high-quality, safe, and effective therapeutics to individuals seeking relief from immunity issues or viral infections. Finally, we commenced shipping VELDONA® Pet cytoprotein supplements in Taiwan during the third quarter of 2023. Formulated to address a variety of health issues in dogs and cats, these supplements are an important new product line for the Company and represent a significant step as we strive to diversify our revenues."
"During 2023, amid widespread downsizing in the healthcare industry, our ability to maintain a stable headcount is a testament to our resilience, capital efficiency, and our cost-effective operations in Taiwan. This stability provides us with a strong foundation, empowering us to develop our business and advance our product pipeline."
"As we move further into 2024, we will continue our strategic pivot away from the sale of COVID-19 antigen rapid test kits. In line with this transition, our near-term priorities encompass sales and marketing of VELDONA® Pet, advancing our flagship VOC POCT candidate, Ainos Flora, and co-developing a VOC sensing platform with our Japanese partners. At the same time, we will advance clinical studies and actively pursue the out-licensing of VELDONA® human drug candidates, including our candidate for treating oral warts in HIV-seropositive patients, which the U.S. FDA has granted Orphan Drug Designation ("ODD"). I believe that our long-term strategic vision will likely yield sustainable, long-term value for our shareholders."
Meng-Lin Sung, Chief Financial Officer of Ainos, commented, "Our strategic initiatives to advance our pipeline and diversify our revenue streams made solid progress in 2023. In 2023, we bolstered our financial position with our US
Full Year 2023 Financial Results
Revenues
Revenues were US
Cost of Revenues
Cost of revenues was US
Gross Profit
In the full year of 2023, gross profit was negative US
Total Operating Expenses
Total operating expenses decreased to US
- R&D expenses increased to US
$7,317,388 in the full year of 2023 from US$6,845,964 in the same period of 2022. Share-based compensation expenses and depreciation and amortization expenses in the full year of 2023 were US$5,252,730 , compared with US$4,711,028 a year ago. When excluding these non-cash expenses, R&D expenses decreased to US$2,064,658 from US$2,134,936 over the same period. - SG&A expenses decreased to US
$5,635,275 from US$8,535,591 in the same period of 2022. Share-based compensation expenses and depreciation and amortization expenses in 2023 and 2022 were US$2,886,216 and US$6,473,546 , respectively. When excluding these non-cash expenses, SG&A expenses increased to US$2,749,059 from US$2,062,045 over the same period.
Net Loss
Net loss attributable to common stock shareholders was US
Balance Sheet
As of December 31, 2023, the Company had cash and cash equivalents of US
Recent Business Developments
On November 6, 2023, the Company announced that it had signed a Memorandum of Understanding ("MoU") with SIDSCO Biomedical Co., Ltd. ("SIDSCO"). The MoU is an important step in Ainos' strategy to expand its product line into the global pet care market. Under the agreement, Ainos and SIDSCO will jointly explore the feasibility of VELDONA®/Cytoprotein contract clinical trials. Ainos intends to conduct animal clinical trials for veterinary investigational medicines in conjunction with SIDSCO, and will provide the technical knowledge, funding, and assistance required for the project.
On November 21, 2023, the Company announced that positive top-line data has been reported from three clinical studies for its VELDONA® low-dose oral interferon formulation as a potential treatment for oral warts in HIV-seropositive patients, which the FDA has granted orphan drug designation. The positive results partially fulfill the hypotheses of the three studies in establishing a safe daily dose, and demonstrate the formulation's superior efficacy compared to a placebo in relieving oral warts in HIV-seropositive individuals.
On November 28, 2023, the Company announced that its contract manufacturer, Swiss Pharmaceutical Co., Ltd. (Taiwan) ("Swiss Pharma"), has completed manufacturing of a Good Manufacturing Practice ("GMP") Clinical Batch of the Company's VELDONA® investigational new drugs.
On December 26, 2023, the Company announced that it is initiating the second phase of co-development of a volatile organic compound (VOC) sensing platform, powered by AI Nose technology, in collaboration with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. The parties aim to finalize the prototype in the third quarter of 2024 and subsequently prepare for mass production.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA® interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's products include VELDONA® clinical-stage human therapeutics, VELDONA® Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. The lead POCT candidate, Ainos Flora, is intended to be a telehealth-friendly POCT for women's health and certain common STIs. To learn more, visit https://www.ainos.com.
Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Safe Harbor Statement
This press release contains "forward-looking statements" about Ainos within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products ; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023 and other reports filed with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's reports filed with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Investor Relations Contact
ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: Ainos.IR@icrinc.com
| Ainos, Inc. | ||||||||
| Balance Sheets | ||||||||
| December 31, | ||||||||
| 2023 | 2022 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 1,885,628 | $ | 1,853,362 | ||||
Accounts receivable | 455 | 201,546 | ||||||
Inventory, net | 167,593 | 595,222 | ||||||
Other current assets | 419,521 | 195,787 | ||||||
Total current assets | 2,473,197 | 2,845,917 | ||||||
Intangible assets, net | 28,283,208 | 32,806,738 | ||||||
Property and equipment, net | 876,572 | 1,375,676 | ||||||
Other Assets | 208,827 | 80,683 | ||||||
Total assets | $ | 31,841,804 | $ | 37,109,014 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Contract liabilities | $ | 112,555 | $ | - | ||||
Convertible notes payable, related party | - | 376,526 | ||||||
Other notes payable, related party | 42,000 | 884,000 | ||||||
Accrued expenses and others current liabilities | 1,182,283 | 1,212,386 | ||||||
Total current liabilities | 1,336,838 | 2,472,912 | ||||||
Senior secured convertible notes measured at fair value | 2,651,556 | - | ||||||
Convertible notes payable - noncurrent | 3,000,000 | - | ||||||
Other notes payable, related party - noncurrent | 270,000 | - | ||||||
Other long-term liabilities | 135,829 | 8,096 | ||||||
Total liabilities | 7,394,223 | 2,481,008 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | 46,778 | 40,023 | ||||||
Common Shares to be issued 162,337 shares and nil as of December 31, 2023 and 2022, respectively | 1,623 | - | ||||||
Additional paid-in capital | 62,555,808 | 58,905,242 | ||||||
Accumulated deficit | (37,886,155 | ) | (24,115,606 | ) | ||||
Accumulated other comprehensive loss- translation adjustment | (270,473 | ) | (201,653 | ) | ||||
Total stockholders' equity | 24,447,581 | 34,628,006 | ||||||
Total liabilities and stockholders' equity | $ | 31,841,804 | $ | 37,109,014 | ||||
| Ainos, Inc. | ||||||||
| Statements of Operations | ||||||||
| Years ended December 31 | ||||||||
| 2023 | 2022 | |||||||
Revenues | $ | 122,112 | $ | 3,519,627 | ||||
Cost of revenues | (375,845 | ) | (2,114,284 | ) | ||||
Gross Profit (loss) | (253,733 | ) | 1,405,343 | |||||
Operating expenses: | ||||||||
Research and development expenses | 7,317,388 | 6,845,964 | ||||||
Selling, General and administrative expenses | 5,635,275 | 8,535,591 | ||||||
Total operating expenses | 12,952,663 | 15,381,555 | ||||||
Loss from operating | (13,206,396 | ) | (13,976,212 | ) | ||||
Non-operating (expenses) income, net | ||||||||
Interest expenses | (144,193 | ) | (53,528 | ) | ||||
Issuance cost of senior secured convertible note measured at fair value | (525,643 | ) | - | |||||
Fair value change for senior secured convertible note | 94,207 | - | ||||||
Other income, net | 12,276 | 23,050 | ||||||
Total non-operating income and expenses, net | (563,353 | ) | (30,478 | ) | ||||
Net loss before income taxes | (13,769,749 | ) | (14,006,690 | ) | ||||
Provision for income taxes | 800 | - | ||||||
Net loss | $ | (13,770,549 | ) | $ | (14,006,690 | ) | ||
Net loss per common shares-basic and diluted | $ | (3.36 | ) | $ | (5.14 | ) | ||
Weighted average common shares used in computing net loss per common share-basic and diluted | 4,098,109 | 2,727,458 | ||||||
SOURCE: Ainos, Inc.
View the original press release on accesswire.com
FAQ
What strategic pivot did Ainos, Inc. focus on in 2023?
What key partnerships did Ainos, Inc. form for expanding its AI Nose technology?
What financial results did Ainos, Inc. report for the full year of 2023?
What recent business developments were highlighted by Ainos, Inc.?
What was the cash and cash equivalents of Ainos, Inc. as of December 31, 2023?
